Abstract

We previous found the expression level of PTEN was low in the chronic lymphocytic leukemia (CLL) patients. To assess the pathogenic contribution of the low expression of PTEN, we determined PTEN-regulating miRNA interference, PTEN promoter methylation and PTEN gene mutation condition in CLL. One hundred and fifty-four previously untreated CLL patients and 200 cases of healthy controls were sequenced in exons 5-9 of PTEN. None of single nucleotide polymorphism site or mutation was detected in the coding sequences of those exons. Methylation of PTEN promoter was found in one (1.33%) of the 75 patients with CLL, but none of the 25 age-matched control subjects. We found that PTEN was a potential target of miR-26a and miR-214, which had been confirmed following dual-luciferase reporter assays, reverse transcription polymerase chain reaction and Western blotting. High expression of miR-26a was associated with advanced Binet stage (P=0.012), p53 aberrations (P=0.014) and inferior time to first treatment (P=0.038), and high expression of miR-214 was only associated with p53 aberrations (P=0.041). Inhibition of miR-26a or miR-214 could induce more apoptosis in primary cultured CLL cells. These findings support miR-26a and miR-214 down-regulate expression of PTEN in CLL, but not PTEN mutation or promoter methylation.

Highlights

  • Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the Western societies [1], but low incidence in Asian countries, including China [2, 3]

  • We found PTEN expression was down-regulated in CLL patients compared to purified B cells from the normal controls, and the low expression level of PTEN was associated with adverse clinical prognosis [14]

  • To study the mechanism of aberrant PTEN expression, we explored the correlation between PTENtargeting miRNAs and PTEN expression in CLL patients

Read more

Summary

Introduction

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the Western societies [1], but low incidence in Asian countries, including China [2, 3]. With the coming of aging society and the westernization of lifestyle, increasing incidence has been reported in recent years in Asia [4]. Common treatments include alkylating agent, purine analogs and immunotherapeutic agents. No current treatment is curative, and all patients eventually relapse [5]. It is urgent to explore the new treatment modality. Several small molecule inhibitors which target kinases in the B cell receptor (BCR) pathway have promising clinical activity, pave the way for a revolution in the treatment of CLL [6]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call